Laboratory testing services
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261200800042C
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $815,099
Award facts
- Opportunity
-
- N02RC8102374 Solicitation number
- Manufacture of SS1P Drug Product Award Notice · Posted Jul 17, 2008
- Contract value 36% obligated
-
- $815,763.00 Current, with exercised options
- $2,293,892.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Kensington, MD 20895, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | -$664 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $62,768 | |
| Change Order | $43,543 | |
| Exercise an Option | $342,034 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $367,418 |
About this award
This is a definitive contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL) for $2,293,892.00. The contract is for laboratory testing services and does not have a set-aside designation. ABL is a foreign-owned, for-profit manufacturer of goods that specializes in the development of gene therapies, vaccines, oncolytics, and immunotherapies. In addition to this contract, ABL holds several Indefinite Delivery Vehicles (IDVs) with federal agencies, including the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Neurological Disorders and Stroke (NINDS), demonstrating its broad capabilities in biopharmaceutical research and development. Through its federal contracts and grants, ABL has contributed to various programs, such as HIV microbicides and biomedical prevention, pediatric drug formulation development, and cancer prevention initiatives.
Quick answers
Who was awarded contract HHSN261200800042C?
HHSN261200800042C was awarded to Advanced Bioscience Laboratories, Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2008.
How much is contract HHSN261200800042C worth?
The government has obligated $815,099 on HHSN261200800042C. Its current value, with exercised options, is $815,763. Its potential value, with all options, is $2,293,892.
Was contract HHSN261200800042C competed?
The extent of competition for HHSN261200800042C was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award